Company intelligence / Profile preview

Illuminare Biotechnologies

Brooklyn, New York, United States

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Illuminare-1, the company's lead candidate, is currently in a first-in-human Phase 1 clinical trial at Memorial Sloan Kettering Cancer Center, focusing on radical prostatectomy to demonstrate safety and initial efficacy in improving nerve visualization. The IND was approved by the FDA in April 2021. The company expects to enter Phase 2 in 2025.[1][4][5]

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

rizedisben

Partnerships

Memorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on Illuminare Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Illuminare Biotechnologies.

Explore the full profile